Sign in
Taking people in United StatesPhase 3

Apixaban doses to prevent blood clots in people with cancer

Compares two apixaban doses with no blood thinner in people with cancer.

Key facts

Who runs it
University of Vermont
Where
Burlington, United StatesSee the site
Trial code
Registry title
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Status
Recruiting
Phase
Phase 3
People taking part
996 people, planned
Started
17 Oct 2025
Expected to end
Aug 2035
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Apixaban 2.5 mg twice daily
  • Apixaban 5 mg once daily
  • No anticoagulation
Record updated
5 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an active solid tumor or lymphoma who are starting or changing cancer treatment and have a medium risk of blood clots.

Age
18 years and older
Sex
All sexes
Disease stage
Active solid tumor or lymphoma. Khorana Risk Score of 2, a medium risk of blood clots.
Earlier treatment
Must be starting a new cancer treatment that works through the whole body, or changing cancer treatment. Cannot be on full-dose blood thinners now.
Biomarker or test result
Khorana Risk Score of 2, worked out from lab and clinical data when treatment starts.

Main reasons for not taking part

  • Active bleeding or high risk of bleeding, such as recent major surgery or brain tumors that may bleed
  • Cannot take apixaban, for example allergy, severe liver disease or certain other drugs
  • Platelet count < 50,000/µL or creatinine clearance < 25 mL/min
  • Life expectancy < 3 months
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Diagnosed with an active solid tumor or lymphoma
  • Starting a new systemic cancer treatment or changing cancer treatment
  • Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)
  • Not currently receiving therapeutic anticoagulation
  • Able to provide informed consent

Who cannot take part

  • Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)
  • Known contraindication to apixaban (e.g., allergy, severe liver disease, dual strong CYP3A4 and P-gp inhibitors)
  • Platelet count < 50,000/µL
  • Creatinine clearance < 25 mL/min
  • Current therapeutic-dose anticoagulation for VTE or atrial fibrillation
  • Life expectancy < 3 months
  • Pregnant or breastfeeding
  • Inability to comply with study procedures

This trial is currently available in United States.

  • University of Vermont Medical CenterBurlington, United StatesContact: Steven Ades, MD, MScTaking people

About the trial

What the trial wants to find out

Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience.

Read full original descriptionShow less

This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE. The study focuses on people who have a "Khorana score" of 2, which puts them at intermediate risk for developing blood clots.

The study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy. Participants will be randomly assigned to one of three groups:

Group 1: Apixaban 2.5 mg twice a day (standard prophylactic dose)

Group 2: Apixaban 5 mg once a day (an alternative, more convenient dose)

Group 3: No anticoagulant (standard care)

Participants will take the assigned treatment (if applicable) for 6 months. Researchers will monitor whether participants develop blood clots, experience serious bleeding events, or die from any cause during the study period.

By comparing these three groups, the researchers hope to learn whether a once-daily dose of apixaban can work as well as the standard twice-daily dose, and whether either dosing strategy is better than no anticoagulation at all. If successful, the study may help increase the safe use of VTE prevention in cancer patients and improve overall outcomes, especially in patients at intermediate risk.

This is a pragmatic trial, meaning it is designed to fit into real-world clinical practice with minimal extra procedures. The study drug is not provided by the sponsor and will be prescribed and filled through usual care channels. Participants and their doctors will decide whether to continue the medication after the study ends.

The 3 groups in the trial

  • Arm 1: Apixaban 2.5 mg Twice Daily ProphylaxisTreatment being tested

    Participants in this arm will receive apixaban 2.5 mg by mouth twice daily (BID) for 6 months. This is the guideline-supported prophylactic dose for VTE prevention in high-risk ambulatory cancer patients.

    Treatment: Apixaban 2.5 mg twice daily

  • Arm 2 Title: Apixaban 5 mg Once Daily ProphylaxisTreatment being tested

    Participants in this arm will receive apixaban 5 mg by mouth once daily for 6 months. This alternative dosing schedule is being tested for its potential to improve adherence and maintain VTE protection in moderately high-risk cancer outpatients.

    Treatment: Apixaban 5 mg once daily

  • No Anticoagulation (Control)Existing treatment, for comparison

    Participants in this arm will not receive any anticoagulant prophylaxis. This approach reflects current standard-of-care practice for many patients with a Khorana Risk Score of 2, where anticoagulation is not routinely prescribed.

    Treatment: No anticoagulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Comparison of Anticoagulant Dosing Strategies to Reduce VTE and Mortality in Cancer Outpatients: A Randomized, Pragmatic Trial
Plain-language title
Apixaban doses to prevent blood clots in people with cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
5 February 2026